Last quarter (Q4 2022), Oryzon Genomics SA's total revenue was €0.00, a decrease of ― from the same quarter last year. In Q4, Oryzon Genomics SA's net income was €-2.32M. See Oryzon Genomics SA’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	€ 0.00	€ 0.00	€ 0.00	€ 0.00	€ 0.00
Cost of Revenue	-	€ -15.23M	€ -9.87M	€ -8.99M	€ -9.85M	€ -6.49M
Gross Profit	-	€ 15.23M	€ 9.87M	€ 8.99M	€ 9.85M	€ 6.49M
Operating Expense	€ 21.05M	€ 20.72M	€ 16.88M	€ 13.28M	€ 13.67M	€ 9.43M
Operating Income	€ 1.12M	€ -5.49M	€ -7.01M	€ -4.29M	€ -3.82M	€ -2.94M
Net Non Operating Interest Income Expense	-	€ -1.11M	€ -449.85K	€ -468.96K	€ -755.76K	€ -800.43K
Other Income Expense	-	-	-	-	-	-
Pretax Income	€ -6.89M	€ -6.56M	€ -7.18M	€ -4.78M	€ -4.58M	€ -3.71M
Tax Provision	€ -2.47M	€ -2.33M	€ -2.49M	€ -1.38M	€ -891.59K	€ -2.54M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	€ -4.42M	€ -4.23M	€ -4.69M	€ -3.40M	€ -3.68M	€ -1.18M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	€ -1.12M	€ 5.49M	€ 7.01M	€ 4.29M	€ 3.82M	€ 2.94M
Net Income From Continuing And Discontinued Operation	€ -4.42M	€ -4.23M	€ -4.69M	€ -3.40M	€ -3.68M	€ -1.18M
Normalized Income	€ -4.42M	€ -4.11M	€ -4.68M	€ -3.40M	€ -3.68M	€ -1.17M
Interest Expense	-	€ 1.12M	€ 455.57K	€ 469.09K	€ 772.19K	€ 803.77K
EBIT	€ 1.29M	€ -5.44M	€ -6.72M	€ -4.31M	€ -3.80M	€ -2.91M
EBITDA	€ 1.29M	€ -5.27M	€ -6.58M	€ -4.16M	€ -3.65M	€ -2.76M

Currency in EUR

Oryzon Genomics SA Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing